Literature DB >> 18813282

Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms.

Annemieke Aartsma-Rus1, Laura van Vliet, Marscha Hirschi, Anneke A M Janson, Hans Heemskerk, Christa L de Winter, Sjef de Kimpe, Judith C T van Deutekom, Peter A C 't Hoen, Gert-Jan B van Ommen.   

Abstract

Antisense oligonucleotides (AONs) can interfere with mRNA processing through RNase H-mediated degradation, translational arrest, or modulation of splicing. The antisense approach relies on AONs to efficiently bind to target sequences and depends on AON length, sequence content, secondary structure, thermodynamic properties, and target accessibility. We here performed a retrospective analysis of a series of 156 AONs (104 effective, 52 ineffective) previously designed and evaluated for splice modulation of the dystrophin transcript. This showed that the guanine-cytosine content and the binding energies of AON-target and AON-AON complexes were significantly higher for effective AONs. Effective AONs were also located significantly closer to the acceptor splice site (SS). All analyzed AONs are exon-internal and may act through steric hindrance of Ser-Arg-rich (SR) proteins to exonic splicing enhancer (ESE) sites. Indeed, effective AONs were significantly enriched for ESEs predicted by ESE software programs, except for predicted binding sites of SR protein Tra2beta, which were significantly enriched in ineffective AONs. These findings compile guidelines for development of AONs and provide more insight into the mechanism of antisense-mediated exon skipping. On the basis of only four parameters, we could correctly classify 79% of all AONs as effective or ineffective, suggesting these parameters can be used to more optimally design splice-modulating AONs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18813282      PMCID: PMC2835096          DOI: 10.1038/mt.2008.205

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  22 in total

Review 1.  Listening to silence and understanding nonsense: exonic mutations that affect splicing.

Authors:  Luca Cartegni; Shern L Chew; Adrian R Krainer
Journal:  Nat Rev Genet       Date:  2002-04       Impact factor: 53.242

2.  Mfold web server for nucleic acid folding and hybridization prediction.

Authors:  Michael Zuker
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

Review 3.  RNA modulation, repair and remodeling by splice switching oligonucleotides.

Authors:  Ryszard Kole; Tiffany Williams; Lisa Cohen
Journal:  Acta Biochim Pol       Date:  2004       Impact factor: 2.149

4.  RESCUE-ESE identifies candidate exonic splicing enhancers in vertebrate exons.

Authors:  William G Fairbrother; Gene W Yeo; Rufang Yeh; Paul Goldstein; Matthew Mawson; Phillip A Sharp; Christopher B Burge
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

5.  Identification of sequence motifs in oligonucleotides whose presence is correlated with antisense activity.

Authors:  O V Matveeva; A D Tsodikov; M Giddings; S M Freier; J R Wyatt; A N Spiridonov; S A Shabalina; R F Gesteland; J F Atkins
Journal:  Nucleic Acids Res       Date:  2000-08-01       Impact factor: 16.971

6.  Computational definition of sequence motifs governing constitutive exon splicing.

Authors:  Xiang H-F Zhang; Lawrence A Chasin
Journal:  Genes Dev       Date:  2004-05-14       Impact factor: 11.361

7.  Incorporating chemical modification constraints into a dynamic programming algorithm for prediction of RNA secondary structure.

Authors:  David H Mathews; Matthew D Disney; Jessica L Childs; Susan J Schroeder; Michael Zuker; Douglas H Turner
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-03       Impact factor: 11.205

8.  ESEfinder: A web resource to identify exonic splicing enhancers.

Authors:  Luca Cartegni; Jinhua Wang; Zhengwei Zhu; Michael Q Zhang; Adrian R Krainer
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

9.  Silencer elements as possible inhibitors of pseudoexon splicing.

Authors:  Manuela Sironi; Giorgia Menozzi; Laura Riva; Rachele Cagliani; Giacomo P Comi; Nereo Bresolin; Roberto Giorda; Uberto Pozzoli
Journal:  Nucleic Acids Res       Date:  2004-03-19       Impact factor: 16.971

10.  Dynamics of co-transcriptional pre-mRNA folding influences the induction of dystrophin exon skipping by antisense oligonucleotides.

Authors:  Keng Boon Wee; Zacharias Aloysius Dwi Pramono; Jian Li Wang; Karl F MacDorman; Poh San Lai; Woon Chee Yee
Journal:  PLoS One       Date:  2008-03-26       Impact factor: 3.240

View more
  56 in total

Review 1.  Challenges posed to the European pharmaceutical regulatory system by highly personalized medicines.

Authors:  John D Johnston; Peter Feldschreiber
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

2.  Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy.

Authors:  Ingrid E C Verhaart; Hans Heemskerk; Tatyana G Karnaoukh; Ingrid G M Kolfschoten; Anne Vroon; Gert-Jan B van Ommen; Judith C T van Deutekom; Annemieke Aartsma-Rus
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

Review 3.  Managing the sequence-specificity of antisense oligonucleotides in drug discovery.

Authors:  Peter H Hagedorn; Bo R Hansen; Troels Koch; Morten Lindow
Journal:  Nucleic Acids Res       Date:  2017-03-17       Impact factor: 16.971

4.  A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model.

Authors:  Maria Grazia Biferi; Mathilde Cohen-Tannoudji; Ambra Cappelletto; Benoit Giroux; Marianne Roda; Stéphanie Astord; Thibaut Marais; Corinne Bos; Thomas Voit; Arnaud Ferry; Martine Barkats
Journal:  Mol Ther       Date:  2017-06-26       Impact factor: 11.454

5.  Exon skipping as a therapeutic strategy applied to an RYR1 mutation with pseudo-exon inclusion causing a severe core myopathy.

Authors:  John Rendu; Julie Brocard; Eric Denarier; Nicole Monnier; France Piétri-Rouxel; Cyriaque Beley; Nathalie Roux-Buisson; Brigitte Gilbert-Dussardier; Marie José Perez; Norma Romero; Luis Garcia; Joël Lunardi; Julien Fauré; Anne Fourest-Lieuvin; Isabelle Marty
Journal:  Hum Gene Ther       Date:  2013-07       Impact factor: 5.695

6.  A recurrent COL6A1 pseudoexon insertion causes muscular dystrophy and is effectively targeted by splice-correction therapies.

Authors:  Véronique Bolduc; A Reghan Foley; Herimela Solomon-Degefa; Apurva Sarathy; Sandra Donkervoort; Ying Hu; Grace S Chen; Katherine Sizov; Matthew Nalls; Haiyan Zhou; Sara Aguti; Beryl B Cummings; Monkol Lek; Taru Tukiainen; Jamie L Marshall; Oded Regev; Dina Marek-Yagel; Anna Sarkozy; Russell J Butterfield; Cristina Jou; Cecilia Jimenez-Mallebrera; Yan Li; Corine Gartioux; Kamel Mamchaoui; Valérie Allamand; Francesca Gualandi; Alessandra Ferlini; Eric Hanssen; Steve D Wilton; Shireen R Lamandé; Daniel G MacArthur; Raimund Wagener; Francesco Muntoni; Carsten G Bönnemann
Journal:  JCI Insight       Date:  2019-03-21

7.  A novel dual lock method for down-regulation of genes, in which a target mRNA is captured at 2 independent positions by linked locked nucleic acid antisense oligonucleotides.

Authors:  Ryohei Takata; Gouki Makado; Ayaka Kitamura; Hajime Watanabe; Tadashi Wada
Journal:  RNA Biol       Date:  2016-02-18       Impact factor: 4.652

Review 8.  Using microRNA as an alternative treatment for hyperlipidemia and cardiovascular disease: cardio-miRs in the pipeline.

Authors:  Elizabeth J Hennessy; Kathryn J Moore
Journal:  J Cardiovasc Pharmacol       Date:  2013-09       Impact factor: 3.105

9.  Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.

Authors:  Yusuke Echigoya; Kenji Rowel Q Lim; Nhu Trieu; Bo Bao; Bailey Miskew Nichols; Maria Candida Vila; James S Novak; Yuko Hara; Joshua Lee; Aleksander Touznik; Kamel Mamchaoui; Yoshitsugu Aoki; Shin'ichi Takeda; Kanneboyina Nagaraju; Vincent Mouly; Rika Maruyama; William Duddy; Toshifumi Yokota
Journal:  Mol Ther       Date:  2017-07-28       Impact factor: 11.454

10.  Therapeutic exon skipping for dysferlinopathies?

Authors:  Annemieke Aartsma-Rus; Kavita H K Singh; Ivo F A C Fokkema; Ieke B Ginjaar; Gert-Jan van Ommen; Johan T den Dunnen; Silvère M van der Maarel
Journal:  Eur J Hum Genet       Date:  2010-02-10       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.